Guangzhou Innocare Pharma Tech Co Ltd

To evaluate the efficacy of ICP-332 in subjects with moderate to severe atopic dermatitis

1. Evaluate the safety and tolerability of ICP-332 in the treatment of adult subjects with moderate to severe atopic dermatitis (AD). 2. Evaluate the efficacy of ICP-332 in the treatment of moderate to severe AD using the Eczema Area and Severity Index (EASI) score. 3. Other efficacy endpoints and patient-reported outcomes of ICP-332 in the treatment of adult subjects with moderate to severe AD. 4. Evaluate the pharmacokinetic (PK) characteristics of ICP-332 in adult subjects with moderate to severe AD.

Primary objective: To evaluate the safety and tolerability of ICP-332 after oral administration in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of ICP-332 in healthy subjects.